RAPT Therapeutics to be Acquired by GSK for $2.2 Billion in All-Cash Tender Offer at $58.00 Per Share
Summary
RAPT Therapeutics has agreed to be acquired by GlaxoSmithKline for approximately $2.2 billion, with shareholders receiving $58.00 per share in cash, representing a significant premium.
Key Events
-
Acquisition Agreement
RAPT Therapeutics has entered into a definitive agreement to be acquired by GlaxoSmithKline LLC (GSK) for approximately $2.2 billion.
-
Tender Offer Price
GSK will commence a tender offer to purchase all outstanding shares of RAPT common stock at a price of $58.00 per share in cash.
-
Significant Premium
The offer price represents a 65% premium to the last closing price (January 16, 2026) and a 37% premium to the 52-week high of RAPT shares.
-
Strategic Rationale
The acquisition is expected to accelerate the development of RAPT's programs, particularly ozureprubart in food allergy, leveraging GSK's global resources.
Analysis
The definitive agreement for GlaxoSmithKline to acquire RAPT Therapeutics at a substantial premium fundamentally alters the investment thesis, providing immediate and significant value to shareholders. The $2.2 billion all-cash deal represents a 65% premium over RAPT's last closing price and a 37% premium over its 52-week high, reflecting strong confidence in RAPT's pipeline, particularly ozureprubart. This strategic acquisition by a major pharmaceutical company ensures RAPT's programs will benefit from extensive resources and infrastructure, de-risking future development and commercialization. Investors should expect the stock price to converge towards the $58.00 offer price, with the transaction anticipated to close in the first quarter of 2026.
At the time of this filing, RAPT was trading at $57.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $972.7M. The 52-week trading range was $5.67 to $42.39. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.